Ivabradine: A new strategy for management of stable angina

British Journal of Hospital Medicine

Volumn 68, Issue 6, 2007, Pages 321-325

  Menown, Ian B A ^a  

^a CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; IVABRADINE; NICORANDIL; NITRIC ACID DERIVATIVE; PLACEBO;

ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; STABLE ANGINA PECTORIS;

EID: 34250863301     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2007.68.6.23576     Document Type: Review

References (28)

1. Allender S, Peto V, Scarborough P, Boxer A, Rayner M (2006) Coronary heart disease statistics. British Heart Foundation, London (http://www.heartstats.org/datapage.asp?id=5712; accessed 16 May 2007)
2. Bartnik M, Ryden L, Ferrari R et al (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 25: 1880-90
3. Borer JS, Fox K, Jaillon P, Lerebours G; for the Ivabradine Investigators Group (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomised, double-blind, multicentered, placebo-controlled trial. Circulation 107: 817-23
4. British National Formulary (2006) Beta-adrenoceptor blocking drugs. BNF 52. 2.4. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London (www.bnf.org.uk; accessed 9 November 2006)
5. Brorsson B, Bernstein SJ, Brook RH, Werkö L (2002) Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87: 140-5
6. Brown H, DiFrancesco D (1980) Voltage-clamp investigations of membrane currents underlying pace-maker activity in rabbit sinoatrial node. J Physiol 308: 331-51
7. ClinicalTrials.gov (2005a) Efficacy and safety of ivabradine on top of atenolol in stable angina pectoris. NCT00202566. (http://clinicaltrials.gov/ct/ show/NCT00202566?order=2; last accessed 15 November 2006)
8. ClinicalTrials.gov (2005b) The BEAUTIFUL study: effects of ivabradine in patients with stable coronary artery disease and left-ventricular systolic dysfunction. NCT00143507 (http://clinicaltrials.gov/ct/show/NCT00143507?order=1; accessed 15 May 2007)
9. Diaz A, Bourassa M, Guertin M-C, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26: 967-74
10. DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16): 1757-65
11. Doig C, Fox KM, Borer JS, Ruzyllo W, Barton J (2006) Selective If inhibition with ivabradine is a novel and effective approach to reduce heart rate in diabetic patients with stable angina. Presented at the Annual Meeting of the British Cardiovascular, Glasgow. http://heart.bmj.com/cgi/content/full/92/ suppl_2/A4
12. Fox K, Garcia MA, Ardissino D et al (2006) Guidelines on the management of stable angina pectoris; executive summary. Task Force on the Management of Stable Angina Pectotis of the European Society of Cardiology. Eur Heart J 27: 1341-81
13. Gibbons RJ, Abrams J, Chatterjee K et al (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107(1): 149-58
14. Gillman MW, Kannel WB, Belanger A, D'Agostino RB (1993) Influence of heart rate on mortality among hypertension: the Framingham Study. Am Heart J 125: 1148-54
15. Habib G (2001) Is heart rate a risk factor in the general population? Dialogues Cardiovasc Med 6: 25-31
16. Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65(9): 547-53
17. Lanza GA, Cianflone D, Rebuzzi AG et al (2006) Prognostic value of ventricular arrhythmias and heart rate variability in patients with unstable angina. Heart 92: 1055-63
18. Lopez-Bescos L, Filipova S, Martos R on behalf of the study investigators (2004) Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. A one-year randomized, double-blind, multicentre trial. Eur Heart J 25: 876
19. Manz M, Reuter M, Lauck G et al (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100: 149-55
20. O'Toole L, Grech ED (2003) Chronic stable angina: treatment options. BMJ 326: 185-8
21. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Bretano C, Jaillon P (1998) Pharmacokinetic-pharmacodynamic modelling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmcol Ther 64: 192-203
22. Ruzyllo W, Ford I, Tendera M et al (2004) Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Eur Heart J 25: 878
23. Servier Laboratories Ltd (2006) Procoralan SmPC. (http://www.medicines. org.uk/searchresult.aspx?search=procoralan; accessed 30 January 2007)
24. Shattock M, Camm AJ (2006) Pure heart rate reduction: the If channels from discovery to therapeutic target. Br J Cardiol 13: 27-35
25. Stettler C, Bearth A, Allemann S et al (2006) QT(c) interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia 50: 186-94
26. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV (2003) The current cost of angina pectoris to the National Health Service in the UK. Heart 89: 838-53
27. Tardif JC, Ford I, Tendera M, Bourassa MG (2005a) Efficacy of Ivabradine, a new selective If inhibitor compared with atenolol in patients with chronic stable angina. Eur Heart J 26: 2529-36
28. Tardif JC, Fox K, Tendera M, Ford I (2005b) Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 26: 580